Sort   by:  
 Page size 
UnknownOptimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.
Not available
S-EPMC4851188 | biostudies-literature
UnknownIntegrative model of the immune response to a pulmonary macrophage infection: what determines the infection duration?
Not available
S-EPMC4169448 | biostudies-literature
UnknownP42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1
Not available
S-EPMC10171579 | biostudies-literature
UnknownRestoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Not available
S-EPMC7140641 | biostudies-literature
UnknownART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.
Not available
S-EPMC6607914 | biostudies-literature
UnknownHow to prevent viremia rebound? Evidence from a PRRSv data-supported model of immune response.
Not available
S-EPMC6352383 | biostudies-literature
UnknownCombination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.
Not available
S-EPMC4454319 | biostudies-literature
UnknownInterest of FDG-PET in the Management of Mantle Cell Lymphoma.
Not available
S-EPMC6465510 | biostudies-literature
UnknownBiological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Not available
S-EPMC4496181 | biostudies-literature
UnknownBCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
Not available
S-EPMC10393035 | biostudies-literature
Sort   by:  
 Page size